• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DOXEPIN Drug Record

  • Summary
  • Interactions
  • Claims
  • DOXEPIN chembl:CHEMBL1628227 Approved

    Alternate Names:

    SINEQUAN
    ZONALON
    P-3693A
    SINEPIN
    DOXEPIN

    Drug Info:

    Drug Indications hypnotic
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antimigraine agent
    Drug Class antidepressive agents, tricyclic
    Year of Approval 1969
    Drug Class antipruritics
    (3 More Sources)

    Publications:

    Stahl, 2008, Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines., CNS Spectr
    Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
    de Graaf C et al., 2011, Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor., J Med Chem
    Cusack et al., 1994, Binding of antidepressants to human brain receptors: focus on newer generation compounds., Psychopharmacology (Berl.)
    Richelson et al., 1984, Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro., J. Pharmacol. Exp. Ther.
    Kano et al., 2004, Decreased histamine H1 receptor binding in the brain of depressed patients., Eur. J. Neurosci.
    Claro et al., 1986, Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex., Eur. J. Pharmacol.
    Figueiredo et al., 1990, Mechanism of action of doxepin in the treatment of chronic urticaria., Fundam Clin Pharmacol
    Tashiro et al., 2004, Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography., J Clin Pharmacol
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Tran et al., 1981, [3H]doxepin interactions with histamine H1-receptors and other sites in guinea pig and rat brain homogenates., Eur. J. Pharmacol.
    Singh et al., 2007, Novel therapeutic usage of low-dose doxepin hydrochloride., Expert Opin Investig Drugs
    Ehlert et al., 1990, The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart., J. Pharmacol. Exp. Ther.
    Beil et al., 1988, Interaction of antidepressants and neuroleptics with histamine stimulated parietal cell adenylate cyclase and H+ secretion., Pharmacology
    Maj et al., 1977, Doxepin as a blocker of central serotonin receptors., Pharmakopsychiatr Neuropsychopharmakol
    Kirchheiner J et al., 2002, Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers., Pharmacogenetics
    Duncan et al., 2007, Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin., Biochem. Pharmacol.
    Hicks JK et al., 2013, Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants., Clin Pharmacol Ther
  • DOXEPIN   HRH2

    Interaction Score: 0.69

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Silenor (SO-101)

    PMIDs:
    2141000 2897127


    Sources:
    TdgClinicalTrial

  • DOXEPIN   CHRM4

    Interaction Score: 0.62

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    7855217 2141000 2329499


    Sources:
    TdgClinicalTrial

  • DOXEPIN   HTR2B

    Interaction Score: 0.61

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    7855217 309138


    Sources:
    TdgClinicalTrial

  • DOXEPIN   HRH1

    Interaction Score: 0.38

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    22007643 7855217 6086881 15255990 3011460 2141000 15286093 19179941 11752352 7238574 17685877


    Sources:
    DTC TdgClinicalTrial TTD

  • DOXEPIN   SLC6A2

    Interaction Score: 0.35

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name doxepin nasal solution,Dolorac
    Novel drug target Established target
    Trial Name Silenor (SO-101)

    PMIDs:
    19179941 9537821


    Sources:
    TdgClinicalTrial TEND

  • DOXEPIN   CHRM5

    Interaction Score: 0.34

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    7855217 2141000 2329499


    Sources:
    TdgClinicalTrial

  • DOXEPIN   CHRM2

    Interaction Score: 0.27

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    7855217 2141000 2329499


    Sources:
    TdgClinicalTrial

  • DOXEPIN   SLC6A4

    Interaction Score: 0.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name doxepin nasal solution,Dolorac
    Novel drug target Established target
    Trial Name Silenor (SO-101)

    PMIDs:
    19179941 9537821


    Sources:
    TdgClinicalTrial TEND

  • DOXEPIN   HTR2C

    Interaction Score: 0.21

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    7855217 309138


    Sources:
    TdgClinicalTrial

  • DOXEPIN   CHRM1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    7855217 2141000 19179941 2329499


    Sources:
    TdgClinicalTrial

  • DOXEPIN   CHRM3

    Interaction Score: 0.2

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    7855217 2141000 2329499


    Sources:
    TdgClinicalTrial

  • DOXEPIN   HTR2A

    Interaction Score: 0.14

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Silenor (SO-101)
    Novel drug target Established target

    PMIDs:
    7855217 19179941 309138


    Sources:
    TdgClinicalTrial

  • DOXEPIN   CYP2C19

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23486447 12360109


    Sources:
    PharmGKB FDA

  • DOXEPIN   KCNH2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    17560554


    Sources:
    PharmGKB

  • DOXEPIN   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12360109


    Sources:
    PharmGKB

  • DOXEPIN   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXEPIN   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    FDA

  • DOXEPIN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: DOXEPIN

    • Version: 01-August-2011

    Alternate Names:
    DOXEPIN Primary Drug Name

    Drug Info:
    Drug Class antipruritics
    Year of Approval 1969
    Drug Class antidepressive agents, tricyclic

    Publications:

  • TdgClinicalTrial: DOXEPIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antimigraine agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: DOXEPIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1628227 ChEMBL Drug ID

    Drug Info:

    Publications:
    de Graaf C et al., 2011, Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor., J Med Chem

  • PharmGKB: doxepin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Kirchheiner J et al., 2002, Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers., Pharmacogenetics
    Hicks JK et al., 2013, Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants., Clin Pharmacol Ther

  • TTD: Doxepin

    • Version: 2020.06.01

    Alternate Names:
    D06FES TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1628227

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Doxepin

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21